Litcius/Paper detail

FGD1 promotes tumor progression and regulates tumor immune response in osteosarcoma via inhibiting PTEN activity

Wei Wu, Doudou Jing, Zibo Meng, Binwu Hu, Binlong Zhong, Xiangyu Deng, Xin Jin, Zengwu Shao

2020Theranostics50 citationsDOIOpen Access PDF

Abstract

Rationale: Mesenchymal cell-derived osteosarcoma is a rare malignant bone tumor affecting children and adolescents. PTEN down-regulation or function-loss mutation is associated with the aggressive of osteosarcoma. Explicating the regulatory mechanism of PTEN might highlight new targets for improving the survival rate of osteosarcoma patients. Methods: The clinical relevance of FGD1 was examined by the TCGA data set, Western blotting and immunohistochemistry of osteosarcoma microarray slides. Functional assays, such as the MTS assay, colony formation assay and xenografts, were used to determine the biological role of FGD1 in osteosarcoma. The protein-protein interaction between FGD1 and PTEN was detected via co-immunoprecipitation. The relationship between FGD1 and PD-L1 was examined by Western blot analysis, RT-qPCR and immunohistochemistry.

Topics & Concepts

OsteosarcomaPTENCancer researchImmune systemTumor progressionChemistryMedicineApoptosisCancerInternal medicineImmunologyPI3K/AKT/mTOR pathwayBiochemistryCancer-related molecular mechanisms researchCancer-related gene regulationCancer Immunotherapy and Biomarkers